APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ustekinumab Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Ustekinumab Biosimilars Industry Growth and Trends Forecast to 2032

27 December 202590 pages

Choose your research edition.

Industry ResearchUstekinumab Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Ustekinumab Biosimilars Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Ustekinumab Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ustekinumab Biosimilars Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ustekinumab Biosimilars Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Ustekinumab Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Ustekinumab Biosimilars include Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, Celltrion, Qyuns Therapeutics, Bio-Thera Solutions and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Ustekinumab Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Ustekinumab Biosimilars market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Ustekinumab Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Ustekinumab Biosimilars.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Ustekinumab Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Ustekinumab Biosimilars Market by Company

Teva

Amgen

Samsung Bioepis

Sandoz

Biocon Biologics

Celltrion

Qyuns Therapeutics

Bio-Thera Solutions

Huadong Medicine

Ustekinumab Biosimilars Segment by Type

Subcutaneous Injection

Intravenous Infusion

Ustekinumab Biosimilars Segment by Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Psoriatic Arthritis

Other

Ustekinumab Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ustekinumab Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ustekinumab Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ustekinumab Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Ustekinumab Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Ustekinumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Subcutaneous Injection Table 2. Major Company of Intravenous Infusion Table 3. Global Ustekinumab Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 5. Global Ustekinumab Biosimilars Sales Market Share in Volume by Type (2021-2026) Table 6. Global Ustekinumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 7. Global Ustekinumab Biosimilars Sales Market Share in Value by Type (2021-2026) Table 8. Global Ustekinumab Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 9. Global Ustekinumab Biosimilars Sales by Type (2027-2032) & (K Units) Table 10. Global Ustekinumab Biosimilars Sales Market Share in Volume by Type (2027-2032) Table 11. Global Ustekinumab Biosimilars Sales by Type (2027-2032) & (US$ Million) Table 12. Global Ustekinumab Biosimilars Sales Market Share in Value by Type (2027-2032) Table 13. Global Ustekinumab Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 14. North America Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 15. North America Ustekinumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 17. Europe Ustekinumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Ustekinumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 21. Latin America Ustekinumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Ustekinumab Biosimilars Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Ustekinumab Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 24. Ustekinumab Biosimilars Industry Trends Table 25. Ustekinumab Biosimilars Industry Drivers Table 26. Ustekinumab Biosimilars Industry Opportunities and Challenges Table 27. Ustekinumab Biosimilars Industry Restraints Table 28. Global Ustekinumab Biosimilars Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Ustekinumab Biosimilars Revenue Market Share by Company (2021-2026) Table 30. Global Ustekinumab Biosimilars Sales by Company (2021-2026) & (K Units) Table 31. Global Ustekinumab Biosimilars Sales Share by Company (2021-2026) Table 32. Global Ustekinumab Biosimilars Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Ustekinumab Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Ustekinumab Biosimilars Major Company Production Sites and Headquarters Table 35. Global Ustekinumab Biosimilars Company, Product Type & Application Table 36. Global Ustekinumab Biosimilars Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Ustekinumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Ustekinumab Biosimilars Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Ustekinumab Biosimilars Sales by Region (2021-2026) & (K Units) Table 41. Global Ustekinumab Biosimilars Sales Market Share in Volume by Region (2021-2026) Table 42. Global Ustekinumab Biosimilars Sales by Region (2021-2026) & (US$ Million) Table 43. Global Ustekinumab Biosimilars Sales Market Share in Value by Region (2021-2026) Table 44. Global Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Ustekinumab Biosimilars Sales by Region (2027-2032) & (K Units) Table 46. Global Ustekinumab Biosimilars Sales Market Share in Volume by Region (2027-2032) Table 47. Global Ustekinumab Biosimilars Sales by Region (2027-2032) & (US$ Million) Table 48. Global Ustekinumab Biosimilars Sales Market Share in Value by Region (2027-2032) Table 49. Global Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Ustekinumab Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 52. Global Ustekinumab Biosimilars Sales Market Share in Volume by Application (2021-2026) Table 53. Global Ustekinumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 54. Global Ustekinumab Biosimilars Sales Market Share in Value by Application (2021-2026) Table 55. Global Ustekinumab Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 56. Global Ustekinumab Biosimilars Sales by Application (2027-2032) & (K Units) Table 57. Global Ustekinumab Biosimilars Sales Market Share in Volume by Application (2027-2032) Table 58. Global Ustekinumab Biosimilars Sales by Application (2027-2032) & (US$ Million) Table 59. Global Ustekinumab Biosimilars Sales Market Share in Value by Application (2027-2032) Table 60. Global Ustekinumab Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 61. North America Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 62. North America Ustekinumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 64. Europe Ustekinumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Ustekinumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 68. Latin America Ustekinumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Ustekinumab Biosimilars Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Ustekinumab Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Teva Ustekinumab Biosimilars Product Portfolio Table 75. Teva Recent Development Table 76. Amgen Company Information Table 77. Amgen Business Overview Table 78. Amgen Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Amgen Ustekinumab Biosimilars Product Portfolio Table 80. Amgen Recent Development Table 81. Samsung Bioepis Company Information Table 82. Samsung Bioepis Business Overview Table 83. Samsung Bioepis Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Samsung Bioepis Ustekinumab Biosimilars Product Portfolio Table 85. Samsung Bioepis Recent Development Table 86. Sandoz Company Information Table 87. Sandoz Business Overview Table 88. Sandoz Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sandoz Ustekinumab Biosimilars Product Portfolio Table 90. Sandoz Recent Development Table 91. Biocon Biologics Company Information Table 92. Biocon Biologics Business Overview Table 93. Biocon Biologics Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Biocon Biologics Ustekinumab Biosimilars Product Portfolio Table 95. Biocon Biologics Recent Development Table 96. Celltrion Company Information Table 97. Celltrion Business Overview Table 98. Celltrion Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Celltrion Ustekinumab Biosimilars Product Portfolio Table 100. Celltrion Recent Development Table 101. Qyuns Therapeutics Company Information Table 102. Qyuns Therapeutics Business Overview Table 103. Qyuns Therapeutics Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio Table 105. Qyuns Therapeutics Recent Development Table 106. Bio-Thera Solutions Company Information Table 107. Bio-Thera Solutions Business Overview Table 108. Bio-Thera Solutions Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio Table 110. Bio-Thera Solutions Recent Development Table 111. Huadong Medicine Company Information Table 112. Huadong Medicine Business Overview Table 113. Huadong Medicine Ustekinumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Huadong Medicine Ustekinumab Biosimilars Product Portfolio Table 115. Huadong Medicine Recent Development Table 116. North America Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. North America Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 118. North America Ustekinumab Biosimilars Sales Market Share by Country (2021-2026) Table 119. North America Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 120. North America Ustekinumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 121. North America Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America Ustekinumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 123. North America Ustekinumab Biosimilars Market Share by Country (2021-2026) Table 124. North America Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America Ustekinumab Biosimilars Market Share Forecast by Country (2027-2032) Table 126. Europe Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Europe Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 128. Europe Ustekinumab Biosimilars Sales Market Share by Country (2021-2026) Table 129. Europe Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 130. Europe Ustekinumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 131. Europe Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe Ustekinumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe Ustekinumab Biosimilars Market Share by Country (2021-2026) Table 134. Europe Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe Ustekinumab Biosimilars Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 138. Asia-Pacific Ustekinumab Biosimilars Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 140. Asia-Pacific Ustekinumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Ustekinumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific Ustekinumab Biosimilars Market Share by Country (2021-2026) Table 144. Asia-Pacific Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific Ustekinumab Biosimilars Market Share Forecast by Country (2027-2032) Table 146. Latin America Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Latin America Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 148. Latin America Ustekinumab Biosimilars Sales Market Share by Country (2021-2026) Table 149. Latin America Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 150. Latin America Ustekinumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America Ustekinumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America Ustekinumab Biosimilars Market Share by Country (2021-2026) Table 154. Latin America Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America Ustekinumab Biosimilars Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 158. Middle East and Africa Ustekinumab Biosimilars Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa Ustekinumab Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 160. Middle East and Africa Ustekinumab Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Ustekinumab Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa Ustekinumab Biosimilars Market Share by Country (2021-2026) Table 164. Middle East and Africa Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa Ustekinumab Biosimilars Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Ustekinumab Biosimilars Distributors List Table 169. Ustekinumab Biosimilars Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Ustekinumab Biosimilars Image Figure 2. Global Ustekinumab Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ustekinumab Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Ustekinumab Biosimilars Sales (2021-2032) & (K Units) Figure 5. Subcutaneous Injection Image Figure 6. Global Subcutaneous Injection Sales YoY Growth (2021-2032) & (K Units) Figure 7. Intravenous Infusion Image Figure 8. Global Intravenous Infusion Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Ustekinumab Biosimilars Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Ustekinumab Biosimilars Market Share by Type 2025 VS 2032 Figure 11. North America Ustekinumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 12. North America Ustekinumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 13. Europe Ustekinumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 14. Europe Ustekinumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Ustekinumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Ustekinumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 17. Latin America Ustekinumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Ustekinumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Ustekinumab Biosimilars Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Ustekinumab Biosimilars Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Ustekinumab Biosimilars Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Crohn's Disease Image Figure 24. Global Crohn's Disease Sales YoY Growth (2021-2032) & (K Units) Figure 25. Ulcerative Colitis Image Figure 26. Global Ulcerative Colitis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Plaque Psoriasis Image Figure 28. Global Plaque Psoriasis Sales YoY Growth (2021-2032) & (K Units) Figure 29. Psoriatic Arthritis Image Figure 30. Global Psoriatic Arthritis Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Ustekinumab Biosimilars Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Ustekinumab Biosimilars Market Share by Application 2025 VS 2032 Figure 35. North America Ustekinumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 36. North America Ustekinumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 37. Europe Ustekinumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 38. Europe Ustekinumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Ustekinumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Ustekinumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 41. Latin America Ustekinumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Ustekinumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Ustekinumab Biosimilars Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Ustekinumab Biosimilars Sales Market Share in Value by Application in 2025 Figure 45. North America Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Ustekinumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Ustekinumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Ustekinumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Ustekinumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Ustekinumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Ustekinumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Ustekinumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Ustekinumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Ustekinumab Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Ustekinumab Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Ustekinumab Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Ustekinumab Biosimilars Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Ustekinumab Biosimilars Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Injection
  • Intravenous Infusion
Applications
  • Crohn's Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Teva
  • Amgen
  • Samsung Bioepis
  • Sandoz
  • Biocon Biologics
  • Celltrion
  • Qyuns Therapeutics
  • Bio-Thera Solutions
  • Huadong Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ustekinumab Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Ustekinumab Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Ustekinumab Biosimilars Market by Type
  6. 1.3.1 Subcutaneous Injection
  7. 1.3.2 Intravenous Infusion
  8. 1.4 Global Ustekinumab Biosimilars Market Size by Type
  9. 1.4.1 Global Ustekinumab Biosimilars Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Ustekinumab Biosimilars Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Ustekinumab Biosimilars Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Ustekinumab Biosimilars Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Ustekinumab Biosimilars Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Ustekinumab Biosimilars Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Ustekinumab Biosimilars Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Ustekinumab Biosimilars Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Ustekinumab Biosimilars Industry Trends
  2. 2.2 Ustekinumab Biosimilars Industry Drivers
  3. 2.3 Ustekinumab Biosimilars Industry Opportunities and Challenges
  4. 2.4 Ustekinumab Biosimilars Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Ustekinumab Biosimilars Revenue (2021-2026)
  2. 3.2 Global Top Players by Ustekinumab Biosimilars Sales (2021-2026)
  3. 3.3 Global Top Players by Ustekinumab Biosimilars Price (2021-2026)
  4. 3.4 Global Ustekinumab Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Ustekinumab Biosimilars Major Company Production Sites & Headquarters
  6. 3.6 Global Ustekinumab Biosimilars Company, Product Type & Application
  7. 3.7 Global Ustekinumab Biosimilars Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Ustekinumab Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Ustekinumab Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Ustekinumab Biosimilars Tier 1, Tier 2, and Tier 3
4 Ustekinumab Biosimilars Regional Status and Outlook
  1. 4.1 Global Ustekinumab Biosimilars Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Ustekinumab Biosimilars Historic Market Size by Region
  3. 4.2.1 Global Ustekinumab Biosimilars Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Ustekinumab Biosimilars Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Ustekinumab Biosimilars Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Ustekinumab Biosimilars Forecasted Market Size by Region
  7. 4.3.1 Global Ustekinumab Biosimilars Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Ustekinumab Biosimilars Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Ustekinumab Biosimilars Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Ustekinumab Biosimilars by Application
  1. 5.1 Ustekinumab Biosimilars Market by Application
  2. 5.1.1 Crohn's Disease
  3. 5.1.2 Ulcerative Colitis
  4. 5.1.3 Plaque Psoriasis
  5. 5.1.4 Psoriatic Arthritis
  6. 5.1.5 Other
  7. 5.2 Global Ustekinumab Biosimilars Market Size by Application
  8. 5.2.1 Global Ustekinumab Biosimilars Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Ustekinumab Biosimilars Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Ustekinumab Biosimilars Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Ustekinumab Biosimilars Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Ustekinumab Biosimilars Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Ustekinumab Biosimilars Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Ustekinumab Biosimilars Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Ustekinumab Biosimilars Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva
  2. 6.1.1 Teva Company Information
  3. 6.1.2 Teva Business Overview
  4. 6.1.3 Teva Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Ustekinumab Biosimilars Product Portfolio
  6. 6.1.5 Teva Recent Developments
  7. 6.2 Amgen
  8. 6.2.1 Amgen Company Information
  9. 6.2.2 Amgen Business Overview
  10. 6.2.3 Amgen Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amgen Ustekinumab Biosimilars Product Portfolio
  12. 6.2.5 Amgen Recent Developments
  13. 6.3 Samsung Bioepis
  14. 6.3.1 Samsung Bioepis Company Information
  15. 6.3.2 Samsung Bioepis Business Overview
  16. 6.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Samsung Bioepis Ustekinumab Biosimilars Product Portfolio
  18. 6.3.5 Samsung Bioepis Recent Developments
  19. 6.4 Sandoz
  20. 6.4.1 Sandoz Company Information
  21. 6.4.2 Sandoz Business Overview
  22. 6.4.3 Sandoz Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sandoz Ustekinumab Biosimilars Product Portfolio
  24. 6.4.5 Sandoz Recent Developments
  25. 6.5 Biocon Biologics
  26. 6.5.1 Biocon Biologics Company Information
  27. 6.5.2 Biocon Biologics Business Overview
  28. 6.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Biocon Biologics Ustekinumab Biosimilars Product Portfolio
  30. 6.5.5 Biocon Biologics Recent Developments
  31. 6.6 Celltrion
  32. 6.6.1 Celltrion Company Information
  33. 6.6.2 Celltrion Business Overview
  34. 6.6.3 Celltrion Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Celltrion Ustekinumab Biosimilars Product Portfolio
  36. 6.6.5 Celltrion Recent Developments
  37. 6.7 Qyuns Therapeutics
  38. 6.7.1 Qyuns Therapeutics Company Information
  39. 6.7.2 Qyuns Therapeutics Business Overview
  40. 6.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio
  42. 6.7.5 Qyuns Therapeutics Recent Developments
  43. 6.8 Bio-Thera Solutions
  44. 6.8.1 Bio-Thera Solutions Company Information
  45. 6.8.2 Bio-Thera Solutions Business Overview
  46. 6.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio
  48. 6.8.5 Bio-Thera Solutions Recent Developments
  49. 6.9 Huadong Medicine
  50. 6.9.1 Huadong Medicine Company Information
  51. 6.9.2 Huadong Medicine Business Overview
  52. 6.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Huadong Medicine Ustekinumab Biosimilars Product Portfolio
  54. 6.9.5 Huadong Medicine Recent Developments
7 North America by Country
  1. 7.1 North America Ustekinumab Biosimilars Sales by Country
  2. 7.1.1 North America Ustekinumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Ustekinumab Biosimilars Sales by Country (2021-2026)
  4. 7.1.3 North America Ustekinumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 7.2 North America Ustekinumab Biosimilars Market Size by Country
  6. 7.2.1 North America Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Ustekinumab Biosimilars Market Size by Country (2021-2026)
  8. 7.2.3 North America Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Ustekinumab Biosimilars Sales by Country
  2. 8.1.1 Europe Ustekinumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Ustekinumab Biosimilars Sales by Country (2021-2026)
  4. 8.1.3 Europe Ustekinumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Ustekinumab Biosimilars Market Size by Country
  6. 8.2.1 Europe Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Ustekinumab Biosimilars Market Size by Country (2021-2026)
  8. 8.2.3 Europe Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Ustekinumab Biosimilars Sales by Country
  2. 9.1.1 Asia-Pacific Ustekinumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Ustekinumab Biosimilars Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Ustekinumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Ustekinumab Biosimilars Market Size by Country
  6. 9.2.1 Asia-Pacific Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Ustekinumab Biosimilars Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Ustekinumab Biosimilars Sales by Country
  2. 10.1.1 South America Ustekinumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Ustekinumab Biosimilars Sales by Country (2021-2026)
  4. 10.1.3 South America Ustekinumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 10.2 South America Ustekinumab Biosimilars Market Size by Country
  6. 10.2.1 South America Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Ustekinumab Biosimilars Market Size by Country (2021-2026)
  8. 10.2.3 South America Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Ustekinumab Biosimilars Sales by Country
  2. 11.1.1 Middle East and Africa Ustekinumab Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Ustekinumab Biosimilars Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Ustekinumab Biosimilars Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Ustekinumab Biosimilars Market Size by Country
  6. 11.2.1 Middle East and Africa Ustekinumab Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Ustekinumab Biosimilars Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Ustekinumab Biosimilars Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Ustekinumab Biosimilars Value Chain Analysis
  2. 12.1.1 Ustekinumab Biosimilars Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Ustekinumab Biosimilars Production Mode & Process
  7. 12.2 Ustekinumab Biosimilars Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Ustekinumab Biosimilars Distributors
  10. 12.2.3 Ustekinumab Biosimilars Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst